Trial Profile
A Long-acting Human Growth Hormone (VRS-317) in Pre-pubertal Children With Growth Hormone Deficiency: A Randomized, Open-label, Multi-center, Phase 1b/2a Study of Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy After Subcutaneous Administration for 6 Months
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somavaratan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms VERTICAL
- Sponsors Versartis
- 07 Sep 2017 According to a Versartis media release, results from this trial will be presented at the 10th International Meeting of Pediatric Endocrinology (IMPE).
- 22 May 2017 Results published in the Versartis Media Release
- 22 May 2017 Three year data from VERTICAL & VISTA trials were presented during the 19th European Congress of Endocrinology (ECE), as reported in a Versartis media release.